New Genes
Enabling the progression and adoption of complex DNA and RNA based technologies to tackle new therapeutic areas (oligonucleotides), to ensure rapid deployment and better outcomes for patients.
FACILITATED BY
KATIE MURRAY | Technical Director at MMIC | CPI
PANELLISTS INCLUDE
BARRIE CASSEY | Pharmaceutical and biotechnology technical expert and leader | CPI
AL BOYLE | Chief Technical Operations and Quality Officer | Alnylam Pharmaceuticals
MARTIN OLBRICH | Scientist in Process Research | Roche
JESKE SMINK | Head of Drug Substance, | Silence Therapeutics